MONTCLAIR, NJ--(Marketwired - September 26, 2016) - FluoroPharma Medical Inc. (FPMI) announced today that data from its Phase II clinical trial for CardioPET were presented at the 21 st Annual Meeting ...
MONTCLAIR, NJ--(Marketwire - February 28, 2013) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission ...
MONTCLAIR, NJ--(Marketwired - October 18, 2016) - FluoroPharma Medical Inc. (FPMI) announced today that it has been collaborating with Philips for data management in conjunction with its Phase II ...
This morning (2/28/2013) FluoroPharma (OTC BB:FPMI) announced that the initial images from phase II trials of their CardioPET imaging agent candidate "show high resolution in the heart and provides ...
Net loss to common (includes the $977k accrued preferred stock dividends expense) and EPS were $4.4 million and ($0.25) in 2011 compared to $954k and ($0.08) for 2012. Cash used in operations was $2.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results